home / stock / bmea / bmea articles
U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday. Shares of Verint Systems Inc. (NASDAQ: VRNT) ...
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes I...
U.S. stocks traded lower, with the Dow Jones index falling more than 100 points on Monday. Shares of Science Applications International Corporation...
Shares of Workday, Inc. (NASDAQ: WDAY) surged in pre-market trading after the company reported upbeat earnings results for its third quarter. Work...
New clinical data from all dosing cohorts (n=62) initiated to date from the escalation portion of COVALENT-111 and long-term (26 weeks) follow-up...
First presentation of clinical data from ongoing COVALENT-101 trial of covalent menin inhibitor BMF-219 as a treatment for patients with liquid t...
Industry veteran and prominent diabetes clinical development expert to oversee Biomea's progressing clinical development of novel covalent m...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-18 04:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, NY / ACCESSWIRE / June 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Biomea Fusion, Inc. ("Biomea" or "the Company") (NASDAQ:BMEA). Investors who purchased Biomea securities are encouraged to obtain additional information...